Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery for protein-protein interactions; raised $80M seed from DCVC and NVIDIA (Jan 2026); oncology and neurodegeneration focus; opens class of previously undruggable targets
Proxima is an AI-driven drug discovery company focused on proteins that control critical biological interactions — specifically targeting protein-protein interactions (PPIs) that have historically been considered undruggable. Founded by researchers with backgrounds in structural biology, machine learning, and medicinal chemistry, Proxima uses AI to design novel therapeutics that can modulate these complex binding interfaces, opening up a vast new class of drug targets for conditions ranging from cancer to neurodegeneration.\n\nThe company's platform integrates protein structure prediction, generative molecular design, and experimental validation in a tightly coupled loop. By leveraging AI models trained on structural and interaction data, Proxima can propose drug candidates targeting previously inaccessible sites on proteins. This approach is particularly relevant for oncology and immunology, where many of the most important biological pathways are mediated by protein complexes that small molecules have struggled to disrupt.\n\nProxima raised an $80M seed round backed by DCVC and NVIDIA in January 2026, one of the largest seed rounds in biotech history. NVIDIA's involvement underscores the computational intensity of the platform and the strategic value of GPU infrastructure partnerships in AI drug discovery. The company is pre-clinical but is building a pipeline of candidates targeting high-value undruggable proteins, with the $80M runway intended to advance multiple programs toward IND filings.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.